Ep #7 | Who is Kiran Mazumdar Shaw Really? And WTF is Biotech?
Executive Summary
Kiran Mazumdar-Shaw tells the Biocon story end to end: a woman locked out of brewing in 1970s India who started with ₹10,000 and a buyback guarantee, survived banks that wanted her father's guarantee, and compounded one technology platform - fermentation and recombinant DNA - from enzymes into statins, insulin and now biosimilars, including a $3 billion deal to become the world's largest biosimilars company. The lessons are portable: hunger and one exciting idea beat capital, keep maximum ownership while sharing equity, divest businesses you will not fund, reinvent before the cliff, and treat wealth as value created rather than money held.
Key Takeaways
Rejected everywhere is a valid starting point
Medical colleges rejected her; every Indian brewery refused to hire a woman brewmaster despite topping her class in Australia, hiding behind 'hostile labor unions'; banks refused a credit line without her father's guarantee, which she declined on principle; her first two employees were retired tractor mechanics who needed jobs too badly to care about a woman boss. Biocon exists because one Irish entrepreneur refused to accept her list of reasons she was the wrong partner - no money, no business experience, and a woman in 1978 India.
One technology platform, four businesses
The through-line of Biocon is fermentation and recombinant DNA expertise redeployed repeatedly: industrial enzymes first (green replacements for chemical processes), then statins via fungal fermentation (Biocon says it now produces roughly half the world's statin APIs), then immunosuppressants for transplant patients, then recombinant human insulin in 2004 - launched at prices that collapsed the animal-insulin market it replaced - and now biosimilars. Her rule, credited to John: be agnostic about what your technology produces and keep asking what else it can do.
Everything has a shelf life - reinvent before the cliff
Kiran's warning to founders: keep doing much of the same and you will hit a cliff when it is too late to change in a hurry. She pivoted Biocon from enzymes to biopharmaceuticals in 2000 precisely when enzymes were doing well, then divested the enzymes business entirely in 2007 to Novozymes because she would not fund it - and watched the buyer grow it five to tenfold on her IP. Do not stay wedded to a historic business you are unwilling to invest in.
An IPO is a currency, not just an exit
Against the common founder regret about going public, Kiran argues a listed valuation is a powerful currency: Biocon used it to build Syngene (research services, about $4.5 billion in value, with 10% monetized for over $300 million to fund an acquisition) and Biocon Biologics (about $6 billion), whose part-cash-part-stock structure made the $3 billion Viatris biosimilars deal possible. Ownership mattered throughout - share equity with the team, but keep the founder's stake dominant as long as possible.
Biosimilars are the next generics - and much harder
Her explanation: generics copy chemically synthesized drugs; biosimilars copy biologics like insulin and monoclonal antibodies, which means starting from a cell line and genetic sequence, matching the innovator's molecule, and running extensive clinical trials because small deviations can be immunogenic - closer to developing a new drug than copying one. Biocon is the only Indian company with biosimilars approved in the US and Europe, eight products approved, a billion-dollar run rate, and about $100 billion of biologics coming off patent in the next decade as the opportunity.
India's window is open, but research is the missing brick
Her policy view: geopolitics has made India the favored destination, digital public infrastructure like Aadhaar and payments is being studied worldwide, and stable economic policy is drawing fund flows - but India spends under 1% of GDP on research versus 4-6% in peer and rival nations; she advocates research-linked incentives alongside production-linked ones, a fully convertible rupee, and education that teaches learning how to learn, or the demographic dividend becomes a China-style aging problem. The Morgan Stanley panel anecdote: asked what she wanted from China she said infrastructure; the Chinese entrepreneur, asked what she wanted from India, said babies.
Resilience as a philosophy, not a trait
On losing her mother and her husband John, and what keeps the drive intact at 70: her mother's parting message - don't grieve too long, life is not to be wasted, it is to be lived. The same philosophy runs through her business positions: retirement means a flexible calendar rather than a cut-off date, philanthropy means large concentrated bets on institutions (she signed the Giving Pledge), and the episode itself ends with her and Nikhil each pledging ₹25 lakh to a charity the audience will choose.
The Conversation Breakdown
From rejected medical aspirant to Australia's only woman brewing...
From rejected medical aspirant to Australia's only woman brewing student
1978: Les Hawkins, ₹10,000, a shed and the birth of
1978: Les Hawkins, ₹10,000, a shed and the birth of Biocon
Enzymes explained
Enzymes explained: green chemistry decades before sustainability
Unilever, IP and the townhouse buyback
Unilever, IP and the townhouse buyback: professionalizing and taking back ownership
Statins to insulin to biosimilars
Statins to insulin to biosimilars: pivoting one platform into biopharma
India's moment
India's moment: digital public goods, research spending and the demographic dividend
Money, loss and legacy
Money, loss and legacy: value creation, the Giving Pledge and her mother's parting words
Core Frameworks & Ideas
Technology-agnostic pivoting
Treat your core capability as a platform and stay agnostic about what it produces: Biocon's fermentation and recombinant DNA skills moved from enzymes to statins to insulin to biosimilars. The discipline is asking, while the current product is still winning, what else the platform can do - because waiting for decline means changing in a hurry at the cliff.
Hunger over resources
Les Hawkins' filter for a founder, which Kiran now applies: not money, not experience - hunger in the belly plus one exciting idea. Her corollary from building Biocon: share equity and delegate to a strong leadership team, but keep the founder's ownership dominant so the company's direction stays driven by the person with the highest vested interest.
Divest what you will not fund
If a historic business needs investment you have decided to give elsewhere, sell it to whoever will fund it best - even your biggest competitor. Biocon's enzymes business went to Novozymes in 2007 and grew five to tenfold on Biocon's own IP; hanging on would have stunted it. The IP itself turned out to be the most enduring asset, validating Unilever's early lesson to always protect innovation.
Actionable Next Steps
- ✓Write down the one idea that makes you hungry enough to start, and your personal list of disqualifiers (no money, no experience, wrong profile) - then treat the list as the excuse it is and take the first reversible step this month.
- ✓Map your own technology or skill platform and list three adjacent products it could produce; start small experiments in the most promising one before your current business peaks.
- ✓Review anything you own - a product, a side project, a holding - that you are unwilling to fund properly, and decide to fund it, fix it or let it go to someone who will.
- ✓If you invest or donate, prefer one or two concentrated bets on institutions over many small fragmented contributions - and where possible, protect the intellectual property you create.
Notable Quotes
“you've got to have hunger in your belly”
“don't be wedded to a historic business”
“life is not to be wasted it's to be lived”
The One Thing to Remember
Hunger plus one idea you find exciting is the real entry ticket to entrepreneurship - everything else Kiran Mazumdar-Shaw needed (money, credibility, a team, even a product market) was acquired along the way, so start before you feel ready.